2 weeks Ago By ABMN Staff
HC Wainwright restated their buy rating on shares of Viking Therapeutics ( NASDAQ:VKTX – Free Report ) in a research report released on Tuesday morning, Benzinga reports. The brokerage currently has a $102.00 target price on the biotechnology company’s stock.
Other equities analysts have also recently issued research reports about the company. StockNews.com upgraded Viking Therapeutics to a “sell” rating in a report on Tuesday, October 15th.
JPMorgan Chase & Co. started coverage on shares of Viking Therapeutics in a research report on Wednesday, September 11th. They set an “overweight” rating and a $80.
00 target price for the company. Morgan Stanley restated an “overweight” rating and issued a $105.00 price target on shares of Viking Therapeutics in a research report on Thursday, September 12th.
B. Riley began coverage on Viking Therapeutics in a report on Friday, November 22nd. They issued a “buy” rating and a $109.
00 price objective for the company. Finally, William Blair restated an “outperform” rating on shares of Viking Therapeutics in a report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, ten have assigned a buy rating and two have issued a strong buy rating to the company’s stock.
According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $109.73.
Read Our Latest Stock Analysis on Viking Therapeutics Viking Therapeutics Stock Performance Viking Therapeutics ( NASDAQ:VKTX – Get Free Report ) last issued its quarterly earnings results on Wednesday, October 23rd. The biotechnology company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.
24) by $0.02. During the same quarter last year, the business posted ($0.
23) earnings per share. As a group, research analysts predict that Viking Therapeutics will post -0.98 EPS for the current fiscal year.
Insider Activity In other Viking Therapeutics news, Director J Matthew Singleton sold 10,300 shares of the business’s stock in a transaction that occurred on Friday, September 20th. The stock was sold at an average price of $69.50, for a total transaction of $715,850.
00. Following the transaction, the director now owns 9,500 shares of the company’s stock, valued at $660,250. The trade was a 52.
02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link . Also, Director Lawson Macartney sold 2,000 shares of the stock in a transaction that occurred on Friday, November 8th.
The shares were sold at an average price of $68.67, for a total value of $137,340.00.
Following the completion of the sale, the director now directly owns 47,965 shares of the company’s stock, valued at approximately $3,293,756.55. The trade was a 4.
00 % decrease in their position. The disclosure for this sale can be found here . Insiders sold 371,117 shares of company stock worth $27,140,009 over the last quarter.
4.70% of the stock is currently owned by company insiders. Institutional Investors Weigh In On Viking Therapeutics A number of institutional investors and hedge funds have recently modified their holdings of VKTX.
Blue Trust Inc. acquired a new position in shares of Viking Therapeutics during the 3rd quarter worth approximately $26,000. Thurston Springer Miller Herd & Titak Inc.
bought a new stake in shares of Viking Therapeutics during the second quarter worth approximately $27,000. GAMMA Investing LLC boosted its holdings in shares of Viking Therapeutics by 124.6% during the third quarter.
GAMMA Investing LLC now owns 438 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 243 shares during the period. Gilliland Jeter Wealth Management LLC acquired a new position in shares of Viking Therapeutics in the third quarter valued at approximately $32,000. Finally, Stone House Investment Management LLC increased its stake in shares of Viking Therapeutics by 66.
7% during the third quarter. Stone House Investment Management LLC now owns 500 shares of the biotechnology company’s stock worth $32,000 after purchasing an additional 200 shares during the period. 76.
03% of the stock is owned by institutional investors. About Viking Therapeutics ( Get Free Report ) Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
See Also Receive News & Ratings for Viking Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter ..
